Biosynth, a leading global provider of essential raw materials and services for the life sciences industry, has announced the appointment of Matt Gunnison as its new Chief Executive Officer and member of the Board of Directors, effective immediately. Kieran Murphy has also been appointed Chairman of the Board.
Matt Gunnison succeeds Urs Spitz, who has guided Biosynth through significant growth and helped establish its strong position in the life sciences sector. Spitz will remain on the Board, continuing to support Biosynth’s strategic direction.
“We are deeply grateful to Urs for his role in transforming Biosynth into the thriving and innovative company it is today,” stated Kugan Sathiyanandarajah, Partner at KKR and Head of Europe for KKR’s Health Care Strategic Growth initiative. “We’re excited to welcome Matt as CEO, whose expertise and leadership will be instrumental in driving Biosynth’s next growth phase.”
Expressing his enthusiasm, Matt Gunnison said, “I’m thrilled to join Biosynth during such a dynamic period. Under Urs’s leadership, the company has built a solid foundation, and I look forward to working with the team to accelerate our growth and continue delivering vital raw materials and services to advance global health.”
Newly appointed Chairman Kieran Murphy added, “I’m honored to take on this role and work closely with Matt and the entire team. With Biosynth’s innovation at the forefront of life sciences, I’m confident in our ability to drive continued success.”
Urs Spitz reflected on Biosynth’s progress, congratulating the new leadership team and expressing his commitment to supporting them as they lead Biosynth into its next chapter.
Matt Gunnison, who co-founded Gamma Biosciences with KKR, brings nearly 20 years of experience in healthcare and life sciences. He has a background in scaling biopharmaceutical manufacturing and previously held senior roles at GE Healthcare, including Head of Corporate Development.
Kieran Murphy, a senior advisor to KKR, brings extensive experience as a former President and CEO of GE Healthcare. He will transition to Biosynth from Gamma Biosciences, where he served as Chairman.
Eric Simpson, formerly Vice President at Gamma Biosciences, joins Biosynth as Head of Corporate Development, adding to the company’s strengthened leadership team.
About Biosynth
Biosynth is a trusted supplier of critical materials, supporting pharmaceutical and diagnostic sectors with research, manufacturing, and distribution capabilities. Known for its broad product portfolio of over a million products and advanced services, Biosynth specializes in complex chemicals, peptides, and key biologics. Headquartered in Staad, Switzerland, the company is supported by investors such as KKR, Ampersand Capital Partners, and its management team.
About KKR
KKR is a leading global investment firm, providing alternative asset management and insurance solutions. It manages investment funds in private equity, credit, and real assets, while partnering with hedge funds. KKR’s insurance subsidiaries offer retirement, life, and reinsurance products under Global Atlantic Financial Group. Learn more at www.kkr.com.
About Ampersand
Founded in 1988, Ampersand Capital Partners is a middle-market private equity firm specializing in healthcare investments. With offices in Boston and Amsterdam, Ampersand leverages private equity and operational expertise to create value alongside portfolio companies. Find more information at www.ampersandcapital.com.
